Are you Dr. Dandrea?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 62 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
Dana Farber Cancer Institute
Boston, MA 02115Phone+1 617-632-2112Fax+1 617-632-5757
Summary
- Dr. Alan Dandrea, MD is a pediatric hematologist/oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts and Pennsylvania. He is affiliated with Dana-Farber Cancer Institute.
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1989 - 1990- Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1986 - 1989
Children's Hospital of PhiladelphiaResidency, Pediatrics, 1983 - 1986
Harvard Medical SchoolClass of 1983
Certifications & Licensure
MA State Medical License 1987 - 2025
PA State Medical License 1985 - 1986- American Board of Pediatrics Pediatrics
Publications & Presentations
PubMed
- 2286 citationsActivating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.Ross L. Levine, Martha Wadleigh, Jan Cools, Benjamin L. Ebert, Gerlinde Wernig
Cancer Cell. 2005-04-01 - 24 citationsHuman MutS and FANCM complexes function as redundant DNA damage sensors in the Fanconi Anemia pathway.Min Huang, Richard D. Kennedy, Abdullah Mahmood Ali, Lisa A. Moreau, Amom Ruhikanta Meetei
DNA Repair. 2011-12-10 - 239 citationsBone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells.Raphael Ceccaldi, Kalindi Parmar, Enguerran Mouly, Marc Delord, Jung Min Kim
Cell Stem Cell. 2012-07-06
Press Mentions
Dana-Farber Clinical Investigators Leverage Rich Patient Samples to Pursue Novel Cancer TherapiesDecember 3rd, 2019
Clinical Trial Underscores Promise of Immunotherapy, in Combination with Second Drug, for Ovarian CancerJuly 13th, 2019
PARI (PARPBP) Suppresses Replication Stress-Induced Myeloid Differentiation in Leukemia CellsJuly 1st, 2019- Join now to see all
